Pathophysiology and Treatment of Myoclonus

Neurologic Clinics

Volumn 27, Issue 3, 2009, Pages 757-777

  Caviness, John N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Electrophysiology; Motor Cortex; Myoclonus; Pathophysiology; Treatment

Indexed keywords

ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; BACLOFEN; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CARDIAC AGENT; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; LEVODOPA; LITHIUM SALT; METHYL BROMIDE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC ANALGESIC AGENT; OXYBATE SODIUM; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PRIMIDONE; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ATAXIA; BRAIN CORTEX; CLINICAL FEATURE; CLINICAL PROTOCOL; CORTICAL MYOCLONUS; CORTICAL SUBCORTICAL MYOCLONUS; DISEASE CLASSIFICATION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROMYOGRAM; HUMAN; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MYOCLONUS; NEUROIMAGING; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PERIPHERAL MYOCLONUS; PRIORITY JOURNAL; REVIEW; SEGMENTAL MYOCLONUS; SUBCORTICAL SUPRASEGMENTAL MYOCLONUS; SYMPTOMATOLOGY;

ANIMALS; ANTICONVULSANTS; BRAIN; DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYOCLONUS;

EID: 67449106356     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.04.002     Document Type: Review

References (57)

1. Marsden C.D., Hallett M., and Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden C.D., and Fahn S. (Eds). Movement disorders (1982), Butterworths, London 196-248
2. Caviness J.N., and Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 3 (2004) 598-607
3. Caviness J.N., Alving L.I., Maraganore D.M., et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 74 (1999) 565-569
4. Shibasaki H. Electrophysiological studies of myoclonus. AAEM minimonograph #30. Muscle Nerve 23 (2000) 321-335
5. Caviness J.N. Clinical neurophysiology of myoclonus. Ch. 32. In: Hallett M. (Ed). Movement disorders. Handbook of clinical neurophysiology vol. 1 (2003), Elsevier, Amsterdam 521-548
6. Ikeda A., Kakigi R., Funai N., et al. Cortical tremor: a variant of cortical reflex myoclonus. Neurology 40 (1990) 1561-1565
7. Caviness J.N., and Kurth M. Cortical myoclonus in Huntington's disease associated with an enlarged somatosensory evoked potential. Mov Disord 12 6 (1997) 1046-1051
8. Uesaka Y., Terao Y., Ugawa Y., et al. Magnetoencephalographic analysis of cortical myoclonic jerks. Electroencephalogr Clin Neurophysiol 99 (1996) 141-148
9. Mima T., Nagamine T., Ikeda A., et al. Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol 43 (1998) 598-607
10. Mima T., Nagamine T., Mikuni N., et al. Cortical myoclonus. Sensorimotor hyperexcitability. Neurology 50 (1998) 933-942
11. Brown P., Farmer S.F., Halliday D.M., et al. Coherent cortical and muscle discharge in cortical myoclonus. Brain 122 (1999) 461-472
12. Caviness J.N., Adler C.H., Sabbagh M.N., et al. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord 18 (2003) 1157-1161
13. Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 26 (1979) 49-84
14. Hauw J.J., Escourolle R., Baulac M., et al. Postmortem studies on posthypoxic and post-methyl bromide intoxication: case reports. Adv Neurol 26 (1979) 201-214
15. De Lean J., Richardson J.C., and Rewcastle N.B. Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor. Adv Neurol 26 (1979) 215-223
16. Tai K.K., Bhidayasiri R., and Truong D.D. Post-hypoxic animal model of myoclonus. Parkinsonism Relat Disord 13 7 (2007) 377-381
17. Snead O.C. Basic mechanisms of generalized absence seizures. Ann Neurol 37 (1995) 146-157
18. Savic I., Pauli S., Jan-Olof T., et al. In vivo demonstration of altered benzodiazepine receptor density in patients with generalized epilepsy. J Neurol Neurosurg Psychiatr 57 (1994) 797-804
19. Deppe M., Kellinghaus C., Duning T., et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 71 (2008) 1981-1985
20. Bradley C.A., Taghibiglou C., Collingridge G.L., et al. Mechanisms involved in the reduction of GABAA receptor 1-subunit expression caused by the epilepsy mutation A322D in the trafficking-competent receptor. J Biol Chem 23 32 (2008) 22043-22050
21. Murai M.J., Sassonia R.C., Zamboni A.H., et al. Characterization of the C-terminal half of human juvenile myoclonic epilepsy protein EFHC1: dimer formation blocks Ca2+ and Mg2+ binding to its functional EF-hand. Arch Biochem Biophys 477 (2008) 131-138
22. Welty T.E. Juvenile myoclonic epilepsy-epidemiology, pathophysiology, and management. Paediatr Drugs 8 5 (2006) 303-310
23. Roze E., Apartis E., Clot F., et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 70 (2008) 1010-1016
24. Chan P., Gonzalez-Maeso J., Dé Rique Ruf F., et al. ε-Sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol 482 (2005) 50-73
25. Yokoi F., Dang M.T., Li J., et al. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in ε-sarcoglycan deficient mice. J Biochem 140 (2006) 141-146
26. Hallett M., Chadwick D., Adam J., et al. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatr 40 (1977) 253-264
27. Brown P. Hyperekplexia. Handbook of clinical neurophysiology (2003), Elsevier, Amsterdam p. 479-89
28. Brown P., Thompson P.D., Rothwell J.C., et al. Axial myoclonus of propriospinal origin. Brain 114 (1991) 197-214
29. Cantello R., Gianelli M., Civardi C., et al. Focal subcortical reflex myoclonus. Arch Neurol 54 (1997) 187-196
30. Westmoreland B.F., Sharbrough F.W., Stockard J.J., et al. Brainstem auditory evoked potentials in 20 patients with palatal myoclonus. Arch Neurol 40 (1983) 155-158
31. Hopkins A.P., and Michael W.F. Spinal myoclonus. J Neurol Neurosurg Psychiatr 37 (1974) 1112-1115
32. Kono I., Ueda Y., Araki K., et al. Spinal myoclonus resembling belly dance. Mov Disord 9 3 (1994) 325-329
33. Davis S.M., Murray N.M.F., Galea-Debono A., et al. Stimulus-sensitive spinal myoclonus. J Neurol Neurosurg Psychiatr 44 (1981) 884-888
34. Di Lazzaro V., Restuccia D., Nardone R., et al. Changes in spinal cord excitability in a patient with rhythmic segmental myoclonus. J Neurol Neurosurg Psychiatr 61 (1996) 641-644
35. Deuschl G., Mischke G., Schenck E., et al. Symptomatic and essential rhythmic palatal myoclonus. Brain 113 (1990) 1645-1672
36. Deuschl G., Toro C., Balls-Sole J., et al. Symptomatic and essential palatal tremor 1. Clinical, physiological and MRI analysis. Brain 117 (1994) 775-788
37. Valls-Sole J. Electrodiagnostic studies of the facial nerve in peripheral facial palsy and hemifacial spasm. Muscle Nerve 36 (2007) 14-20
38. Jankovic J., and Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 43 (1986) 1025-1031
39. Brown P., Steiger M.J., Thompson P.D., et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 8 (1993) 63-68
40. Ikeda A., Shibasaki H., Tashiro K., et al. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. Mov Disord 11 (1996) 691-700
41. Koskiniemi M., Vleymen B., Hakamies L., et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatr 64 (1998) 344-348
42. Fedi M., Reutens D., Dubeau F., et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 58 (2001) 781-786
43. Frucht S.J., Louis E.D., Chuang C., et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 57 (2001) 1112-1114
44. Genton P., and Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2 (2000) 209-212
45. Obeso J.A., Artieda J., Rothwell J.C., et al. The treatment of severe action myoclonus. Brain 112 (1988) 765-777
46. Kyllerman M., and Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 29 (1998) 109-114
47. Frucht S.J., Houghton W.C., Bordelon Y., et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 65 (2005) 1967-1970
48. Wallace S.J. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 29 (1998) 147-154
49. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 5 (1996) 149-151
50. Sheth R.D., and Gidal B.E. Intravenous valproic acid for myoclonic status epilepticus. Neurology 54 (2000) 1201
51. Magarinos-Ascone C.M., Regidor I., Martinez-Castrillo J.C., et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatr 76 (2005) 989-991
52. Caviness J.N., Forsyth P.A., Layton D.D., et al. The movement disorder of adult opsoclonus. Mov Disord 10 (1995) 22-27
53. Pless M., and Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 46 (1996) 583-584
54. Ensink R.J.H., Vingerhoets H.M., Schmidt C.W., et al. Treatment for severe palatoclonus by occlusion of the eustachian tube. Otol Neurotol 24 (2003) 714-716
55. Bryce G.E., and Morrison M.D. Botulinum toxin treatment of essential palatal myoclonus tinnitus. J Otolaryngol 27 (1998) 213-216
56. Lagueny A., Tison G., Burbaud P., et al. Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord 14 (1999) 182-185
57. Carnero-Pardo C., Sanchez-Alvarez J.C., Gomez-Camello A., et al. Myoclonus associated with thoracodorsal neuropathy. Mov Disord 13 6 (1998) 971-972